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) reduced the size of infarct and improved both cardiac function and survival in 46 a murine model of myocardial infarction (Boufenzer et al. 2015) . In that study, LR12 (5 mg/kg) 47 was intraperitoneally (IP) administered once a day for 5 days. This therapeutic scheme should be 48 advantageously replaced by a single injection of a sustained-release formulation. Moreover, LR12 49 oxidizes spontaneously in aqueous media with a short half-life (t1/2) (approximately 14 hours in 50 phosphate buffer saline (PBS) in vitro, and 0.5 hour in blood ex vivo): a disulfide bridge is formed 51 between two peptides, generating a dimer ( Figure 1B) . While still to be confirmed by further 52 investigation, preliminary experiments on cells suggested that the dimer is devoid of 53 pharmacological activity. Consequently, the formulation should both sustain LR12 release for at 54 least a 5-day period and, as much as possible, protect the drug from degrading by dimerization. 55
In this contribution, the in vitro and in vivo release of LR12 (both the monomer and its main product 56 of degradation, i.e. the dimeric form) from in situ forming implants have been evaluated. In situ 57 4 forming implants are liquid formulations which, when injected into aqueous environments, 58 precipitate as solid polymeric matrices entrapping the drug (Parent et al. 2013a ). Sustained releases 59 obtained with in situ forming implants have been described in the literature for a wide range of 60 drugs with various physicochemical properties. Herein, poly-lactide-co-glycolide (PLGA, 61
Resomer RG502H, 50:50 ratio LA:GA) and poly-lactide (PLA, Resomer R203S) were used as 62 biocompatible biodegradable polymers due to their frequent use in in situ forming formulations 63 and their lack of toxicity. Polymers were solubilized (18.7% w/w) in triacetin (TA, 74.8% w/w) 64 before adding the drug (6.5% w/w). The concentration of peptide used in the formulation allowed 65 to subcutaneously inject a dose of 80 mg LR12/kg to the animals. This can be compared to the total 66 dose of 25 mg/kg of free LR12 administered via several IP injections in the study, which 67 demonstrated the benefit of LR12 in myocardial infarction (Boufenzer et al. 2015 ). This dose is 68 compatible with a slow delivery of LR12 from the reservoir formulation during the time of 69 experiment, and it is likely without safety issues. Additionally, with this concentration, the 70 viscosity of the formulation remained suitable for an easy injection. 71
Formulations were prepared and in vitro release experiments were performed in physiological 72 buffer saline according to previously reported protocols (Parent et al. 2013b ). An HPLC-UV 73 method was developed, then validated for selectivity, precision, accuracy and linearity according 74 to the FDA guidelines, and used to quantify LR12 (monomer and dimer) released in the aqueous 75 medium (Figure 2 ). The chromatographic system was the same as previously described ( . Remaining LR12 was also extracted from the retrieved implants and quantified 110 as described above for the in vitro study. At autopsy, no sign of irritation or inflammation of the 111 tissues surrounding the implants was observed, whatever the polymer used (Representative 112 photograph of extraction is supplied in Supplementary data S1). 113
After one single administration of in situ forming implants, LR12 monomer was detected at 114 therapeutic concentrations (between 100 and 400 ng/mL) for a week (Figure 3) . The area under 115 the concentration-time curve (AUC07 days) was calculated using the trapezoidal rule and was 116 normalized by the received dose ( Table 1) . The highest observed plasma concentration (Cmax) and 117 the time required to reach Cmax (Tmax) were obtained from the concentration-time curves. Results 118 indicated that in situ forming formulations significantly improved LR12 monomer bioavailability 119 by a factor 50, without any difference between PLGA and PLA. This can be explained by the 120 sustained-release properties of the in situ forming formulations, which increase the circulation time 121 of LR12, and by the protection of monomer from degradation because it was encapsulated into the 122 polymeric matrices. Although LR12 remaining inside the implants was mainly under the monomer 123 form, the proportion of dimer inside the in vivo implants increased within time (4.3 ± 1.7 % at day 124 7 After one week, more than 95% of the initial load was released. Compared with these in vivo 126 results, better LR12 protection (> 90% remaining as monomer after 3 weeks in the implants) and 127 more sustained release (up to 3 weeks) with in situ forming implants were observed in vitro. to a smooth and sustained profile at therapeutic concentrations for 7 days. As a result, this single 140 injection could be an interesting alternative to the current therapeutic scheme (free drug 5 mg/kg, 141 daily injection for 5 days) proposed in myocardial infarction (Boufenzer et al. 2015) . PLGA 142 formulations should probably be preferred over PLA ones, because they will be degraded faster, 143 while offering the same monomer bioavailability in this case, but with lower burst and less dimer 144 blood exposure (dimer AUC/dose increased by 12 for PLGA implants compared to IP 145 administration and by 18 for PLA ones, Table 1 
